|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-8-31
|
|
pubmed:abstractText |
We conducted a phase II study of combination chemotherapy with paclitaxel (Pac) and irinotrecan (CPT) to determine the qualitative and quantitative toxicities and efficacy of the combination against advanced nonsmall cell lung cancer (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1537-453X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
358-60
|
|
pubmed:meshHeading |
pubmed-meshheading:17762435-Adult,
pubmed-meshheading:17762435-Aged,
pubmed-meshheading:17762435-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17762435-Camptothecin,
pubmed-meshheading:17762435-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:17762435-Female,
pubmed-meshheading:17762435-Humans,
pubmed-meshheading:17762435-Lung Neoplasms,
pubmed-meshheading:17762435-Male,
pubmed-meshheading:17762435-Maximum Tolerated Dose,
pubmed-meshheading:17762435-Middle Aged,
pubmed-meshheading:17762435-Paclitaxel,
pubmed-meshheading:17762435-Prognosis,
pubmed-meshheading:17762435-Survival Rate,
pubmed-meshheading:17762435-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced nonsmall cell lung cancer.
|
|
pubmed:affiliation |
Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan. foshita@kcch.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
